AstraZeneca PLC (AZN)

33.87
0.42 1.20
NYSE : Health Care
Prev Close 34.29
Open 34.01
Day Low/High 33.47 / 34.27
52 Wk Low/High 26.97 / 34.88
Volume 4.18M
Avg Volume 5.32M
Exchange NYSE
Shares Outstanding 2.53B
Market Cap 79.80B
EPS 1.10
P/E Ratio 14.14
Div & Yield 1.90 (6.00%)

Latest News

Hep C Business Slow-Down Could Hamper Bristol-Myers' Future

Hep C Business Slow-Down Could Hamper Bristol-Myers' Future

The company's hepatitis C drug division is expected to see losses in the second half of the year.

AstraZeneca (AZN) Leading In Pre-Market Activity

AstraZeneca (AZN) Leading In Pre-Market Activity

Trade-Ideas LLC identified AstraZeneca (AZN) as a pre-market leader candidate

AstraZeneca Earnings, Sales Edge Above Forecasts

AstraZeneca Earnings, Sales Edge Above Forecasts

CEO Soriot says the company's pipeline is progressing well, and predicts a boost to full-year earnings from a decline in the pound.

3 Stocks Boosting The Health Care Sector Higher

3 Stocks Boosting The Health Care Sector Higher

TheStreet highlights 3 stocks pushing the health care sector higher today.

Analysts' Actions -- GE, Nordstrom, Rockwell Collins, Sprint and More

Analysts' Actions -- GE, Nordstrom, Rockwell Collins, Sprint and More

Here are Tuesday's top research calls, including upgrades for GE, Nordstrom and Sprint, and a downgrade for Rockwell Collins.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AZN, BOOT, CFCB, CMFN, CSS, GE, KFS, NBHC, OMN, OSB, PCH, SBFG, UNFI Downgrades: ATAI, FCCY Initiations: CNV Read on to get TheStreet Quant Ratings' detailed report:

Global Week Ahead: Report Card Time for European Banks, BOJ Monetary Policy Meeting

Global Week Ahead: Report Card Time for European Banks, BOJ Monetary Policy Meeting

Expect a barrage of key indicators and earnings from companies including Deutsche Bank, LVMH, Diageo and AB InBev.

European Stock Markets Mixed After Signs of Brexit Damage

European Stock Markets Mixed After Signs of Brexit Damage

Purchasing managers' surveys point toward a slowdown in U.K services and manufacturing

Clouds With a Golden Lining: Enterprise Software Targets

Clouds With a Golden Lining: Enterprise Software Targets

As large tech groups and private sponsors shop for software companies, outfits with enterprise clients and cloud services have come into focus.

Relypsa Finally Finds Buyer, but Potential Seen For Rival Bid

Relypsa Finally Finds Buyer, but Potential Seen For Rival Bid

Shares of Relypsa are rallying after the company announced it has agreed to be acquired by Galenica Group in a $1.53B deal.

Heavy Volume And Pre-Market Movement For AstraZeneca (AZN)

Heavy Volume And Pre-Market Movement For AstraZeneca (AZN)

Trade-Ideas LLC identified AstraZeneca (AZN) as a pre-market mover with heavy volume candidate

AstraZeneca (AZN) Is Today's Storm The Castle Stock

AstraZeneca (AZN) Is Today's Storm The Castle Stock

Trade-Ideas LLC identified AstraZeneca (AZN) as a "storm the castle" (crossing above the 200-day simple moving average on higher than normal relative volume) candidate

TAGRISSO® (OSIMERTINIB) Met Primary Endpoint In Phase III 2nd-Line Lung Cancer Trial

TAGRISSO® (OSIMERTINIB) Met Primary Endpoint In Phase III 2nd-Line Lung Cancer Trial

AstraZeneca today announced that the AURA3 Phase III trial met its primary endpoint, demonstrating superior progression-free survival (PFS) compared to standard platinum-based doublet chemotherapy.

AstraZeneca (AZN) Stock Advancing on Patent Litigation Resolution

AstraZeneca (AZN) Stock Advancing on Patent Litigation Resolution

AstraZeneca (AZN) has resolved a patent litigation with Sandoz for a hormonal therapy drug.

Theresa May to Be Appointed New U.K. Prime Minister

Theresa May to Be Appointed New U.K. Prime Minister

Corporate governance changes are among the policy flagships unveiled by the successor to David Cameron.

Heavy Early Morning Activity On AstraZeneca (AZN)

Heavy Early Morning Activity On AstraZeneca (AZN)

Trade-Ideas LLC identified AstraZeneca (AZN) as a pre-market mover with heavy volume candidate

AstraZeneca (AZN) Stock Up, Argus Research Initiates Coverage

AstraZeneca (AZN) Stock Up, Argus Research Initiates Coverage

Shares of AstraZeneca (AZN) are up today as Argus Research initiates coverage of the company with a ‘hold’ rating.

How Will AstraZeneca (AZN) Stock Be Affected by Generic Copies?

How Will AstraZeneca (AZN) Stock Be Affected by Generic Copies?

AstraZeneca’s (AZN) drug Crestor is under pressure from cheaper generic versions.

'Mad Money' Lightning Round: You Should Be Buying Visa

'Mad Money' Lightning Round: You Should Be Buying Visa

Cramer says Wynn is fantastic but he's avoiding Valeant.

Jim Cramer's 'Mad Money' Recap: Thank the Short-Sellers for This Continued Rally

Jim Cramer's 'Mad Money' Recap: Thank the Short-Sellers for This Continued Rally

When short-sellers get caught leaning the wrong way, that's a recipe for explosive moves to the upside, Cramer says.

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

AstraZeneca (AZN) Moving On Heavy Pre-Market Trading

AstraZeneca (AZN) Moving On Heavy Pre-Market Trading

Trade-Ideas LLC identified AstraZeneca (AZN) as a pre-market mover with heavy volume candidate

Sanofi's Likely Sweetener for Medivation Panned

Sanofi's Likely Sweetener for Medivation Panned

The French drugmaker is reportedly thinking about including a CVR in its $9.3 billion bid for Medivation, but the move is unlikely to be enough to entice the target's shareholders.

AstraZeneca Likely to Grind Lower

Barring a strong rally over $31 that has follow-through, we look for AZN to slowly erode.

AstraZeneca, Teva Resolve Their Patent Row Over Diabetes Product

AstraZeneca, Teva Resolve Their Patent Row Over Diabetes Product

The settlement allows Teva to commercialize its generic version of Byetta in the U.S.

AstraZeneca (AZN) Leading In Pre-Market Activity

AstraZeneca (AZN) Leading In Pre-Market Activity

Trade-Ideas LLC identified AstraZeneca (AZN) as a pre-market leader candidate